The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer

ABSTRACT Tumor infiltrating lymphocytes have been associated with a better prognostic and with higher response rates in patients treated with checkpoint inhibiting antibodies, suggesting that strategies promoting tumor inflammation may enhance the efficacy of these currently available therapies. Our aim was thus to develop a new vaccination platform based on cold-inducible RNA binding protein (CIRP), an endogenous TLR4 ligand generated during inflammatory processes, and characterize whether it was amenable to combination with checkpoint inhibitors. In vitro, CIRP induced dendritic cell activation, migration and enhanced presentation of CIRP-bound antigens to T-cells. Accordingly, antigen conjugation to CIRP conferred immunogenicity, dependent on immunostimulatory and antigen-targeting capacities of CIRP. When applied in a therapeutic setting, vaccination led to CD8-dependent tumor rejection in several tumor models. Moreover, immunogenicity of this vaccination platform was enhanced not only by combination with additional adjuvants, but also with antibodies blocking PD-1/PD-L1, CTLA-4 and IL-10, immunosuppressive molecules usually present in the tumor environment and also induced by the vaccine. Therefore, priming with a CIRP-based vaccine combined with immune checkpoint-inhibiting antibodies rejected established B16-OVA tumors. Finally, equivalent activation and T-cell stimulatory effects were observed when using CIRP in vitro with human cells, suggesting that CIRP-based vaccination strategies could be a valuable clinical tool to include in combinatorial immunotherapeutic strategies in cancer patients.

[1]  Antoni Ribas,et al.  Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.

[2]  Thomas C. Mitchell,et al.  The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4 , 2007, Science.

[3]  L. Diaz,et al.  Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer , 2013, Journal of immunotherapy.

[4]  R. Steinman,et al.  Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses , 2006, The Journal of experimental medicine.

[5]  J. Prieto,et al.  Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. , 2011, Cancer research.

[6]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[7]  Haidong Dong,et al.  TLR3-Stimulated Dendritic Cells Up-regulate B7-H1 Expression and Influence the Magnitude of CD8 T Cell Responses to Tumor Vaccination1 , 2009, The Journal of Immunology.

[8]  S. Akira,et al.  TLR signalling and the function of dendritic cells. , 2005, Chemical immunology and allergy.

[9]  R. Steinman,et al.  Differential Antigen Processing by Dendritic Cell Subsets in Vivo , 2007, Science.

[10]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[11]  S. H. van der Burg,et al.  Distinct Uptake Mechanisms but Similar Intracellular Processing of Two Different Toll-like Receptor Ligand-Peptide Conjugates in Dendritic Cells* , 2007, Journal of Biological Chemistry.

[12]  M. Fukumoto,et al.  Effects of ischemia and H2O2 on the cold stress protein CIRP expression in rat neuronal cells. , 1999, Free radical biology & medicine.

[13]  J. Prieto,et al.  Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells , 2011, Hepatology.

[14]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[15]  E. Jaffee,et al.  Cancer Vaccines , 1997, Current protocols in human genetics.

[16]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[17]  K. Rock,et al.  How dying cells alert the immune system to danger , 2008, Nature Reviews Immunology.

[18]  J. Prieto,et al.  The Extra Domain A from Fibronectin Targets Antigens to TLR4-Expressing Cells and Induces Cytotoxic T Cell Responses In Vivo1 , 2007, The Journal of Immunology.

[19]  L. Zitvogel,et al.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.

[20]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[21]  R. Kirschner,et al.  Oxygen-regulated expression of the RNA-binding proteins RBM3 and CIRP by a HIF-1-independent mechanism , 2004, Journal of Cell Science.

[22]  J. Prieto,et al.  Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis. , 2010, Vaccine.

[23]  I. Mellman,et al.  β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10 , 2015, Proceedings of the National Academy of Sciences.

[24]  J. Prieto,et al.  Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[26]  A. Fornace,et al.  Identification of Several Human Homologs of Hamster DNA Damage-inducible Transcripts , 1997, The Journal of Biological Chemistry.

[27]  R. Steinman,et al.  In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.

[28]  C. Horak,et al.  Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. J. Conesa,et al.  Cryo-soft X-ray tomography as a quantitative three-dimensional tool to model nanoparticle:cell interaction , 2016, Journal of Nanobiotechnology.

[30]  S. Akira,et al.  Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway , 2003, Science.

[31]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[32]  A. Sandler,et al.  Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model , 2015, PloS one.

[33]  S. Steinberg,et al.  Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[34]  L. Butterfield.  Cancer vaccines , 2015, BMJ : British Medical Journal.

[35]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[36]  Laurie A. Minns,et al.  Selective TRIF-Dependent Signaling by a Synthetic Toll-Like Receptor 4 Agonist , 2012, Science Signaling.

[37]  R. Koup,et al.  HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Allison,et al.  Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. , 2009, Cancer research.

[39]  Carl G. Figdor,et al.  Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting , 2007, Nature Reviews Immunology.

[40]  D. Filippov,et al.  TLR ligand-peptide conjugate vaccines: toward clinical application. , 2012, Advances in immunology.

[41]  K. Tracey,et al.  Cold-inducible RNA-binding protein (CIRP) triggers inflammatory responses in hemorrhagic shock and sepsis , 2013, Nature Medicine.

[42]  J. Lasarte,et al.  Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination , 2016, Oncoimmunology.

[43]  I. Melero,et al.  Therapeutic vaccines for cancer: an overview of clinical trials , 2014, Nature Reviews Clinical Oncology.

[44]  D. Stephens,et al.  Differential Induction of the Toll-Like Receptor 4-MyD88-Dependent and -Independent Signaling Pathways by Endotoxins , 2005, Infection and Immunity.

[45]  J. Prieto,et al.  Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. , 2011, Journal of hepatology.

[46]  C. Horak,et al.  Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma , 2014, Clinical Cancer Research.

[47]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.